1. Introduction {#sec1}
===============

Infectious mononucleosis (IM) is a common disease affecting mainly adolescents and young adults, usually causing fever, sore throat, fatigue, lymphadenopthy, and splenomegaly. The etiology of the disease is a widely disseminated DNA virus, the Epstein--Barr virus (EBV), a member of the herpes virus family. The genome of the virus consists of approximately 85 genes located on a double-strand DNA helix of 177.000 pair of bases \[[@B1]\]. It is estimated that 90% of the global population has been exposed to the virus, but the vast majority of the individuals remain asymptomatic during the infection. When symptoms are present, they are usually mild and the syndrome is self-limited.

EBV has a lymphotropic behavior, primarily affecting B cells and secondarily epithelial cells. In vitro, the expression of the viral genome inside the affected lymphocytes gives them the potential to become immortal \[[@B2]\]. Additionally, the virus has the ability of latent infection of a subset of memory B cells; therefore, it can remain lifelong hidden in lymphoid cells, initiating an interplay between the virus and immune system response \[[@B3]\]. The dysregulation of this interaction between the virus and the immune response gives a rationale for the association of EBV infection with certain autoimmune conditions \[[@B4], [@B5]\]. In addition, the expression of the latent genes of the virus in the infected cells is considered the key factor for its oncogenic activity \[[@B2]\].

As mentioned above, EBV infection has an asymptomatic course or it is accompanied by symptoms of IM. The main laboratory finding in IM is the extreme lymphocytosis, due to the effect of the virus in the specific CD8 T cells. The infection usually resolves without sequelae, but in a minority of cases, severe complications such as airway obstruction, meningoencephalitis, hemolytic anemia, thrombocytopenia, and splenic rupture can develop. Hepatic involvement in IM is very common, but cholecystitis is extremely rare. Herein, we report a case of acalculous cholecystitis due to EBV infection and we review the relevant literature.

2. Case Report {#sec2}
==============

A 15-year-old female was hospitalized in the Internal Medicine Department of the General Hospital of Kalamata, Western Greece. Initially, she presented to the emergency department complaining of a 4-day history of low-grade fever up to 38.5°C, sore throat, mild cough, sharp abdominal pain, mainly in the epigastric area, and nausea. Physical examination revealed sensitivity in palpation in both right and left upper abdomen quadrants, normal bowel sounds, and no abdominal distention. Additionally, bilateral cervical and axillary lymphadenopathy, tonsillar enlargement with exudates, and a palpable spleen were noticed. Liver size was within normal range, and there was no jaundiced colouring of the sclera. Laboratory findings on admission and during hospitalization are shown in [Table 1](#tab1){ref-type="table"}.

Abdominal ultrasound revealed thickening of the gallbladder wall to 20 mm and pericholecystic edema. Distention of the gallbladder was not evident. The spleen was enlarged to 16 cm, and the liver size was within upper normal limits. No stones or dilatation of the biliary tract were reported. Based on these findings, the diagnosis of acute acalculous cholecystitis was made and the patient was admitted to the Internal Medicine Department for further investigation and treatment. The patient was treated with the administration of intravenous fluids and antibiotics (cefoxitin 1 gr tds and clindamycin 600 mg qds). The patient manifested intense nausea and a couple of vomiting episodes on day 2 and 3 of hospitalization. Her cardiovascular and respiratory function remained stable. At the same time, liver enzymes remained elevated equally to the levels of admission. In the follow-up ultrasound, no remarkable changes were reported. Blood and urine cultures were negative. Serological tests, both heterophile antibody test and IgM antibodies against EBV capsid antigen, confirmed the diagnosis of infectious mononucleosis. Serological tests for hepatitis A, B, C, CMV, HIV, and Toxoplasma Gondi were negative. Seven days after admission, the patient was on a good clinical status, fever was resolved, the appetite had improved, and the abdominal pain had also disappeared. A new ultrasound examination on day 6 of admission revealed a total remission of the previous abnormal findings. The patient was discharged on day 8 in a good clinical status. Reassessment 2 weeks later in the Outpatients clinic of the Hospital revealed no clinical or laboratory abnormalities.

3. Literature Review {#sec3}
====================

3.1. Methods {#sec3.1}
------------

To identify relevant publications of interest, we conducted a PubMed search on December 2018 using the terms "Epstein--Barr, infectious mononucleosis, EBV, and cholecystitis." For the purposes of this review, we limited the search to "Humans" and considered only manuscripts referring to adults. Articles in languages besides English were excluded. We also reviewed the bibliographies of all identified manuscripts to identify additional relevant publications. For the purposes of this review, we included all types of publications, including case reports, case series, and review articles, regardless of publication date.

3.2. Results {#sec3.2}
------------

From the electronic search, we identified 89 articles published in English language. Fifty-three articles reported pediatric cases (patients below 14 years of age) or were irrelevant to our subject and were removed from our search results. Check for duplicates removed 13 more articles, and finally 23 case reports were left and were included in our review. The manual search returned six more cases. Overall, we collected 29 articles describing 30 cases of AAC due to EBV infection in adult patients. The literature search results are summarized in [Table 2](#tab2){ref-type="table"}.

Clinical presentation, laboratory and imaging findings, and complications and outcomes of EBV-related AAC have been reviewed extensively in the past in a couple of reviews \[[@B23], [@B30]\]. Abdominal pain remains the most common symptom. Sore throat and pharyngitis, lympadenopathy, abdominal tenderness, and Murphy\'s sign are also common findings. Elevation of ALT, AST, ALP, and bilirubin in various degrees is also reported. The most common imaging finding is an increase in gallbladder wall thickness. From our search, we identified 20 cases in which antibiotics were administered. All but two patients were treated conservatively. One immunosuppressed male patient underwent cholecystectomy, and his course was complicated by acute cholestatic hepatitis, cold agglutinin-associated hemolytic anemia, and pneumonia. Histology findings were not reported \[[@B10]\]. The second patient who underwent surgery was a 25-years-old immunocompromised female \[[@B33]\]. The postoperative course was uncomplicated. The pathology report of the removed gallbladder showed AAC. All patients had a full recovery the following weeks after hospitalization.

Twenty-nine from the 31 adult patients described in the literature were females. Only two patients underwent surgery. In the first patient for whom surgery was performed, operation probably aggravated the patient\'s course. The patient received high doses of corticosteroids and had a good outcome after 19 days of hospitalization \[[@B10]\]. Another patient who also received corticosteroids improved rapidly \[[@B29]\]. In the second patient who underwent surgery, operation improved her symptoms \[[@B33]\].

Acalculous cholecystitis represents 5--10% of all cases of cholecystitis \[[@B34]\]. The etiology of acalculous cholecystitis is diverse. Main causes are critical illness, sepsis, trauma, surgery, severe burns, parenteral nutrition, prolonged fasting, cancer, infections (both viral and bacterial), and autoimmune disorders, such as systemic lupus erythematosus and systemic vasculitis \[[@B35], [@B36]\]. Viral agents and especially EBV are not considered common causes of acute acalculous cholecystitis, but sporadic cases have been previously described in the literature.

The diagnosis of acute acalculous cholecystitis, especially in critically ill patients, remains a clinical challenge. Clinical and laboratory findings combined with imaging findings will finally lead to diagnosis. Fever and right upper quadrant abdominal pain are the major clinical manifestations. Leucocytosis and abnormal liver tests (AST, ALT, ALP, *γ*-GT, and bilirubin) are also present, but not specific for cholecystitis. Ultrasound criteria include gallbladder wall thickness, pericholecystic fluid (halo)/subserosal edema, intramural gashydrops, gallbladder distention, and the presence of echogenic bile. Ultrasound remains the most useful utility for the diagnosis of ACC, but in uncertain cases, computed tomography and cholescintigraphy using ^99m^Tc are reasonable imaging alternatives to establish the diagnosis \[[@B35]\].

Due to the diverse etiology of AAC, different theories about its pathophysiology have arisen. When ACC is the result of critical illness or surgery, the related mechanisms are hypovolemia, shock, ischemia, and secondary bacterial infection from intestinal Gram-negative bacteria \[[@B37]\]. In cases that AAC follows prolonged fasting or parenteral nutrition, bile stasis is considered the key involved factor \[[@B37]\]. Bile stasis results to increased intraluminal gallbladder pressure and secondary decreased blood perfusion, ischemia, and inflammation. In sepsis, the release of proinflammatory mediators to the systemic circulation, the dissemination of the infectious agent to the bile and the concurrent immunodeficiency might explain the reports of AAC \[[@B38]\]. In cases of autoimmune diseases, ischemia due to visceral vasculitis is the implicating causative agent \[[@B39]\]. Endothelial dysfunction and vasculitis are also implicated in cases that AAC is the result of uncommon infections, such as leptospirosis and scrub typhus \[[@B40], [@B41]\]. It is obvious that in a patient with AAC more than one among the aforementioned mechanisms can be present, depending on the patient\'s underlying disease.

In cases of acalculous cholecystitis due to EBV infection, the pathophysiology still remains obscure. Direct invasion of the gallbladder, as EBV can infect epithelial cells, has been proposed, but this theory has not been clearly proved in the few cases that surgery was performed \[[@B10], [@B23], [@B33], [@B42]\]. Fretzayas et al. based on scintigraphic data proposed that cholecystitis due to EBV infection may not represent a true cholecystitis, but rather a billiary dyskenisia \[[@B43]\]. This theory is not fully accepted, as in many cases, there was just a mild elevation of ALP and bilirubin, not compatible with severe biliary pathology \[[@B23]\]. The most intriguing observation reviewing the cases of EBV-related cholecystitis is that, in the vast majority of the cases, the patient\'s gender is female. The most adequate explanation is that production of eicosanoids, which play a role in the pathogenesis of gallbladder disease, seems to be related to gender and estrogen levels \[[@B23], [@B44]\].

4. Discussion {#sec4}
=============

The fact that female gender predisposes for certain autoimmune conditions has provided us the motive to further explore the hypothesis that EBV cholecystitis may represent some kind of autoimmune manifestation of IM, taking in mind the lymphotropic behavior of the virus and the virus interaction with the human immune system. Reviewing the literature, we identified one case of EBV cholecystitis where inflammation of the gallbladder has been accompanied by a skin rash, due to dermal vasculitis. The vasculitis was documented with a biopsy, showing lymphocytic infiltrates surrounding the walls of small vessels in the dermis accompanied by plumping of endothelial cells \[[@B29]\]. Another report of EBV cholecystitis accompanied by renal dysfunction with massive proteinuria referred to a 2-year-old patient. The authors underline the key role of the host immune response to EBV in the extent and degree of clinical features of the primary EBV infection \[[@B45]\]. The hypothesis that EBV cholecystitis is an abnormal immune response to primary EBV infection is also supported by the favorable results that glucorticoids had on the course of acalculous EBV cholecystitis in a couple of complicated cases \[[@B10], [@B29]\].

An adequate number of vasculitis reports caused by EBV infection are identified in the literature \[[@B46]--[@B51]\]. It is interesting that some of these cases represent localized forms of vasculitis affecting only a single organ. Barrett et al. published in 2015 the histological findings of seven patients with Epstein--Barr Virus Vulvar Ulceration (Lipschütz Disease). All but one specimen exhibited a lymphocytic arteritis (lymphocytes infiltrating and disrupting the artery wall). A diffuse and/or angiocentric predominately lymphocytic infiltrate was found in all cases \[[@B49]\]. Ulcers finally resolved in a short period, usually without the need of medical intervention.

Viral causes of vasculitis besides EBV are also described in the literature. Based on the severity of the clinical presentation, some of the patients with virus-triggered vasculitis received only supportive treatment, while others received antivirals and glucorticoids. Patients\' outcomes were generally positive, suggesting that a benign self-limited course is the natural history of virus-associated vasculitis. This could be another clue that comes to an agreement with the benign course of the patients with EBV cholecystitis, such as described in our patient. In addition, single organ gallbladder vasculitis is a well-described form of localised vasculitis \[[@B52]\]. Viruses such as HBV and HCV have been identified as causative agents in some of these cases. It would be reasonable to speculate that an analogous mechanism could explain gallbladder involvement in cases of EBV-associated acalculous cholecystitis.

We report herein the case of an acalculous cholecystitis in a female adolescent, and we support the hypothesis that EBV-related vasculitis may be the underlying pathogenetic mechanism. Therefore, treatment with glucorticoids could be a useful therapeutic option. The lack of histopathology specimens makes our hypothesis difficult to be proven. Perhaps further studies in the future will elucidate the exact mechanism, which causes this rare manifestation of EBV infection. We hope that our paper will be a motivation for our colleagues to retrospectively review unpublished or published cases of EBV-related AAC that have undergone surgery and investigate the validity of our hypothesis.

5. Conclusion {#sec5}
=============

Acalculous cholecystitis is a well-recognized complication of EBV primary infection, and clinicians should be aware of this rare clinical entity. The female gender seems to strongly predispose for this complication. In the vast majority of the cases, inflammation subsides without the need of surgical intervention and vasculitis may be the major underlying mechanism. Further larger case series and histologic confirmation are warranted.
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###### 

Laboratory test results during the course of hospitalization.

  Day of hospitalization       1st     2nd     3rd    4th    5th    8th (discharge day)
  ---------------------------- ------- ------- ------ ------ ------ ---------------------
  White blood cells (/mm^3^)   10.18   10.01   8.64   8.1    5.82   5.11
  Neut (%)                     16.9    13.8    20.8   14.8   17.7   24.4
  Lymph (%)                    66.7    70.8    65.0   75.2   69.1   64.2
  PLT (10^3^/mm^3^)            120     120     140    160    189    177
  Hct (%)                      33.3    31.6    33.9   33.2   33.1   33.8
  AST (IU/L)                   106     93      95            78      
  ALT (IU/L)                   217     172     144           108     
  ALP (IU/L)                   421     406     326           348     
  *γ*-GT (IU/L)                177     171     151           176     
  TBIL (mg/dL)                 0.84    0.54                          
  DBIL (mg/dL)                 0.32    0.20                          

Neut: neutrophils, lymph: lymphocytes, PLT: platelets, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, *γ*-GT: gamma glutamyltransferase, TBIL: total bilirubin, DBIL: direct bilirubin.

###### 

Clinical and demographic characteristics of the present and previous cases of EBV-related cholecystitis.

  Authors, year                                      Age (years), sex   Country           Treatment              Surgery
  -------------------------------------------------- ------------------ ----------------- ---------------------- ---------
  1\. Yoshie et al. \[[@B6]\], 2004                  15 female          Japan             Supportive             No
  2\. Koch et al. \[[@B7]\], 2007                    53 female          The Netherlands   Supportive             No
  3\. Iaria et al. \[[@B8]\], 2008                   18 female          Italy             Antibiotics            No
  4\. Pelliccia et al. \[[@B9]\], 2008               14 female          Italy             Supportive             No
  5\. Hagel et al. \[[@B10]\], 2009                  21 female          Germany           Antibiotics/steroids   Yes
  6\. Cholongitas et al. \[[@B11]\], 2009            19 female          Greece            Supportive             No
  7\. Yang et al. \[[@B12]\], 2010                   20 female          Korea             Antibiotics            No
  8\. Chalupa et al. \[[@B13]\], 2009                22 female          Czech Republic    Antibiotics            No
  9\. Arya et al. \[[@B14]\], 2010                   16 female          USA               Antibiotics            No
  10\. Nagdev and Ward \[[@B15]\], 2011              18 female          USA               Antibiotics            No
  11\. Beltrame et al. \[[@B16]\], 2012              29 female          Italy             Antibiotics            No
  12\. Dylewski \[[@B17]\], 2012                     22 female          Canada            Antibiotics            No
  13\. Carrascosa et al. \[[@B18]\], 2012            22 female          Spain             Supportive             No
  14\. Strehle et al. \[[@B19]\], 2014               14 female          UK                Antibiotics            No
  15\. Celik et al. \[[@B20]\], 2014                 48 female          Turkey            Antibiotics            No
  16\. Gagneux-Brunon et al. \[[@B21]\], 2014        18 female          France            Antibiotics            No
  17\. Gagneux-Brunon et al. \[[@B21]\], 2014        20 female          France            Antibiotics            No
  18\. Pawlowska-Kamieniak et al. \[[@B22]\], 2015   17 female          Poland            Antibiotics            No
  19\. Agergaard and Larsen \[[@B23]\], 2015         34 female          Denmark           Antibiotics            No
  20\. Alkhoury et al. \[[@B24]\], 2015              15 female          USA               Supportive             No
  21\. Branco et al. \[[@B25]\], 2015                16 female          Portugal          Antibiotics            No
  22\. Majdalani et al. \[[@B26]\], 2016             16 female          Lebanon           Antibiotics            No
  23\. Ono et al. \[[@B27]\], 2016                   33 female          Japan             Antibiotics            No
  24\. Koufakis and Gabranis \[[@B28]\], 2016        21 male            Greece            Supportive             No
  25\. Sheybani et al. \[[@B29]\], 2016              13 female          Iran              Steroids               No
  26\. Yesilbagz et al. \[[@B30]\], 2017             30 female          Turkey            Antibiotics            No
  28\. Cameron et al. \[[@B31]\], 2018               18 female          Canada            Supportive             No
  29\. Hohn et al. \[[@B32]\], 2018                  24 male            Germany           Supportive             No
  30\. Rezkallah et al. \[[@B33]\], 2018             25 female          USA               Supportive             Yes
  31\. Present case                                  15 female          Greece            Antibiotics            No
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